Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study

Table 2

Changes in bone markers.

Variables	Pretreatment	Posttreatment	Difference^†	𝑃
𝑛 (%)	75 (100.0)	73 (97.3)	73 (97.3)
Osteocalcin ECLIA (ng/mL)	17.7 ± 18.6	13.7 ± 16.0	4.0 ± 15.9	<0.0001
Bone ALP (U/L)	25.9 ± 16.2	21.8 ± 11.2	4.2 ± 14.3	0.004
DKK-1 (pmol/L)	136.4 ± 86.3	116.3 ± 58.8	20.2 ± 78.6	0.035
sRANKL (total, pmol/L)	75.1 ± 86.8	48.4 ± 47.2	28.1 ± 101.6	0.011
OPG (pmol/L)	3.9 ± 1.8	4.0 ± 1.9	−0.1 ± 1.1	0.464
sRANKL/OPG ratio	22.2 ± 34.4	13.5 ± 16.1	9.4 ± 36.6	0.037

ECLIA: electrochemiluminescence immunoassay.
^†Pretreatment value − posttreatment value.